New York, NY – For decades, the role of regulatory T (Treg) cells in cancer has presented a perplexing paradox. In most solid tumors, an abundance of these immune cells, known for their ability to put the brakes on the immune system, is consistently linked to poorer patient outcomes. Their presence weakens the body’s crucial ability to attack and eliminate cancerous cells. However, colorectal cancer (CRC) has long stood as a confounding exception, where higher numbers of Treg cells within tumors have been associated with improved survival. This inexplicable pattern has baffled oncologists and immunologists alike, hindering the development of targeted therapies.
A groundbreaking new study from researchers at the Sloan Kettering Institute (SKI) at Memorial Sloan Kettering Cancer Center (MSK) has now offered a definitive explanation, resolving this long-standing mystery. The pivotal findings, published in the prestigious scientific journal Immunity, reveal that the impact of Treg cells in CRC is far more nuanced than previously understood. The critical discovery is that not all Treg cells are created equal; what truly matters is not merely their quantity, but their distinct subtype and the specific roles they play within the tumor microenvironment. This revelation could dramatically improve immunotherapy strategies for the vast majority of colorectal cancer patients and potentially extend to other cancers arising in "barrier tissues" like the skin, stomach, mouth, and throat.
The Enigma of Regulatory T Cells: From Immune Guardians to Cancer’s Accomplices
Regulatory T cells are vital components of the adaptive immune system, serving as essential guardians of immune homeostasis. Their primary function is to maintain "immune tolerance," ensuring that the immune system distinguishes between genuine threats (like pathogens) and harmless entities (such as the body’s own cells, beneficial microbes, or everyday foods). By suppressing overactive immune responses, Tregs prevent autoimmune diseases and maintain a delicate balance within the body.
However, in the context of cancer, this suppressive capacity often becomes a liability. In many solid tumors, cancerous cells exploit Tregs, recruiting them to the tumor site where they then suppress the anti-tumor immune response mounted by effector T cells, particularly cytotoxic CD8+ T cells. This immunological dampening allows tumors to evade destruction and proliferate unchecked, leading to worse prognoses for patients with high Treg infiltration. The conventional wisdom, therefore, painted Tregs as universally detrimental in the fight against cancer.
Colorectal Cancer: A Puzzling Exception to the Rule
Colorectal cancer, which collectively ranks as the second leading cause of cancer-related death when considering both men and women according to the American Cancer Society, consistently defied this general understanding. For years, observational studies showed that CRC patients whose tumors were rich in Treg cells often experienced longer survival rates. This counterintuitive correlation presented a significant challenge to researchers attempting to leverage immunotherapy, as it suggested that broadly targeting and depleting all Treg cells might not be beneficial, and could even be harmful, in CRC. Without understanding the underlying mechanism, developing effective Treg-modulating therapies for CRC remained an elusive goal.
Decades of Pioneering Research Culminate in a Breakthrough
The new study represents the culmination of more than two decades of foundational research led by Dr. Alexander Rudensky, a co-senior author of the study and the Chair of the Immunology Program at MSK. Dr. Rudensky is widely recognized as one of the world’s foremost experts on regulatory T cells, whose pioneering work has been instrumental in establishing the critical role of Tregs in immune tolerance, elucidating their development, function, and influence on various disease states, including cancer. This deep, historical understanding of Treg biology provided the essential bedrock for the current breakthrough.
The interdisciplinary study was expertly guided by first authors Dr. Xiao Huang, a postdoctoral researcher in the Rudensky Lab; Dr. Dan Feng, a former MSK Medical Oncology fellow now at the Icahn School of Medicine at Mount Sinai; and Dr. Sneha Mitra, a postdoctoral researcher in the lab of computational biologist Dr. Christina Leslie, the study’s other senior author. Their collaborative efforts, blending advanced immunological techniques with sophisticated computational analysis, were crucial to unraveling the complex immunological landscape of colorectal tumors.
Focusing on the Most Common Form of Colorectal Cancer
A key aspect of this research was its focus on the most prevalent form of colorectal cancer: microsatellite stable (MSS) tumors with proficient mismatch repair (MMRp). This subtype accounts for a substantial 80% to 85% of all CRC cases. Unfortunately, these MSS-MMRp tumors are notoriously challenging to treat with existing immunotherapies, particularly checkpoint inhibitors, which have revolutionized treatment for other cancer types.
In stark contrast, earlier research at MSK and elsewhere demonstrated the remarkable efficacy of checkpoint inhibitors against colorectal cancers characterized by high microsatellite instability (MSI-H) and mismatch repair deficiency (dMMR). For these patients, immunotherapy alone can often lead to profound responses, in many cases allowing them to avoid invasive surgery, aggressive chemotherapy, and radiation. The limited success of immunotherapy in the majority of CRC patients (MSS-MMRp) underscored the urgent need for novel therapeutic strategies, making the MSK team’s findings particularly impactful.
A Tale of Two Treg Subtypes with Opposing Effects
To decipher the unique immune environment of common colorectal cancers, the research team employed a highly sophisticated mouse model developed at MSK. This model meticulously mirrors the genetic alterations, disease progression, and intricate immune milieu observed in human colorectal tumors, providing an invaluable platform for detailed mechanistic studies.
Through meticulous experimentation, the researchers made a pivotal discovery: tumor-associated Treg cells in CRC do not represent a homogeneous population. Instead, they segregate into two distinct groups based on their production of a specific signaling molecule, or cytokine, called interleukin-10 (IL-10). One group produces IL-10, while the other does not.
The team then undertook a series of precise experiments involving the selective removal of each Treg group from the mouse models. These targeted manipulations allowed them to observe, with unprecedented clarity, the divergent effects of each subtype on tumor growth.
IL-10-Positive Treg Cells: The Unexpected Protectors
The first major revelation concerned the IL-10-positive Treg cells. Far from promoting tumor growth, these cells were found to actively slow it down. Their protective mechanism involves reducing the activity of another type of immune cell known as Th17 cells, which produce interleukin-17 (IL-17). IL-17 is a cytokine known to act as a growth signal for various tumors, including CRC. By dampening Th17 cell activity and IL-17 production, the IL-10-positive Tregs effectively deprive the tumor of a crucial growth stimulant. Intriguingly, these beneficial Treg cells were found to be more commonly located in the healthy tissue immediately adjacent to the tumor, rather than deeply embedded within it. When the researchers selectively eliminated these IL-10-positive Treg cells, tumors in the mouse models grew more quickly, unequivocally demonstrating their protective role.
IL-10-Negative Treg Cells: The Immune Suppressors
Conversely, the IL-10-negative Treg cells exhibited the more conventionally harmful effect. These cells directly suppress powerful anti-cancer immune defenders, most notably cytotoxic CD8+ T cells, which are renowned for their ability to identify and destroy cancerous cells. By inhibiting CD8+ T cell activity, the IL-10-negative Tregs create an immunosuppressive environment that allows the tumor to thrive. Unlike their beneficial counterparts, this detrimental subtype was predominantly found within the tumor itself, strategically positioned to neutralize anti-tumor responses. When these IL-10-negative Treg cells were specifically eliminated, tumors in the mouse models became significantly smaller, confirming their role in fueling tumor progression.
Patient Data Confirms the Findings and Explains the Paradox
A crucial step in validating these preclinical findings was to confirm their relevance in human disease. The MSK team meticulously analyzed tumor samples obtained from patients with colorectal cancer. In these human samples, they successfully identified the same two distinct populations of IL-10-positive and IL-10-negative Treg cells, mirroring their observations in the mouse models.
To further solidify the clinical significance, the researchers analyzed outcomes for over 100 colorectal cancer patients. The results provided compelling evidence: patients whose tumors contained higher levels of the beneficial IL-10-positive Treg cells indeed experienced longer overall survival. Conversely, patients whose tumors were enriched with the harmful IL-10-negative Treg cells faced poorer clinical outcomes. This direct correlation elegantly resolved the long-standing CRC paradox, demonstrating that the overall number of Tregs was misleading; it was the balance and specific functions of these two distinct subtypes that dictated patient prognosis.
"This research shows how important these positive cells are," stated Dr. Huang, emphasizing the profound implications of the discovery. "And it highlights the urgent need to develop therapies that can selectively eliminate the harmful Tregs while preserving the helpful ones. A blunt instrument that targets all Tregs would be counterproductive."
Paving the Way for Precision Immunotherapy: Targeting CCR8
The findings not only explain a biological enigma but also suggest a highly promising path forward for improving treatment for the majority of colorectal cancer patients. According to Dr. Rudensky, who is also a Howard Hughes Medical Institute Investigator, the key lies in selective targeting.
The researchers discovered a critical distinguishing feature: the harmful IL-10-negative Treg cells express high levels of a specific protein called CCR8 on their surface. These are the cells primarily responsible for suppressing the anti-tumor immune response and are predominantly located within the tumor microenvironment.
This discovery builds directly upon earlier, pioneering work from Dr. Rudensky’s lab, led by breast cancer surgeon Dr. George Plitas. That previous research had already shown that CCR8 is highly expressed on tumor Treg cells in breast cancer and a wide array of other human cancers. This established CCR8 as a generalizable marker for detrimental tumor-associated Tregs. The implication was clear: antibodies designed to specifically target and deplete CCR8-expressing cells could offer a powerful new therapeutic strategy. Such an approach could selectively remove only the harmful Treg cells, thereby unleashing the immune system to effectively attack tumors while leaving the beneficial, immune-regulatory Treg cells intact elsewhere in the body.
"This idea of using CCR8-depleting antibodies, which was pioneered at MSK, is the main target of global efforts to bring regulatory T cell-based immunotherapy to the clinic," Dr. Rudensky affirmed, underscoring the international significance of this therapeutic avenue. Multiple clinical trials are currently underway at MSK and other leading institutions worldwide, rigorously testing this innovative approach both as a standalone therapy and in combination with existing immunotherapies. The new study provides robust scientific justification and significantly strengthens the case for deploying this selective CCR8-targeting strategy in colorectal cancer, and potentially far beyond.
Beyond Colorectal Cancer: Similar Immune Patterns in Other Barrier Tissues
The MSK team recognized the potential for their findings to extend beyond CRC. To explore this, they undertook an expansive analysis of a large dataset comprising T cells from 16 different cancer types. Their investigation revealed that the same crucial divisions between IL-10-positive and IL-10-negative Treg cells appeared in several other cancers, specifically those affecting the skin and the lining of the mouth, throat, and stomach.
"What these tissues have in common is that immune cells play a critical role in constantly defending and repairing them as they’re exposed to microbes and environmental stresses," explained Dr. Mitra, who spearheaded the intricate data analysis and is co-mentored by Dr. Leslie and Dr. Rudensky. These "barrier tissues" are constantly interacting with the external environment, necessitating a finely tuned immune system that can both defend against pathogens and tolerate harmless substances.
This observation suggests a profound biological principle at play: the dual nature of Treg cells might be a conserved mechanism in cancers arising from tissues that routinely face environmental challenges. Consequently, the therapies designed to selectively remove IL-10-negative Treg cells in colorectal cancer hold significant promise for also being effective against these other cancers originating in barrier tissues. This broadens the potential impact of the MSK discovery considerably.
The Nuance of Metastatic Disease: A Different Immune Balance
While the study offers immense hope for primary colorectal tumors, the researchers also delved into the complex immune landscape of metastatic disease. When they examined colorectal cancer that had spread to the liver, they observed a notably different immune pattern.
In these metastatic tumors, the balance was heavily skewed: the harmful IL-10-negative Treg cells greatly outnumbered the beneficial IL-10-positive cells. This stark shift in composition indicated a more aggressive, immunosuppressive environment in the metastatic setting. Crucially, unlike primary tumors where selective depletion was key, removing all Treg cells in this metastatic context actually caused the tumors to shrink.
This finding highlights a critical lesson: treatment strategies must be highly nuanced and account for both the specific tissue involved and the stage of the disease. What works for a primary tumor might need to be adapted or even reversed for metastatic lesions. This insight underscores the importance of precision medicine, where therapies are tailored not just to the cancer type, but to its precise location and progression stage.
A Collaborative Triumph and Future Directions
The MSK study is a testament to the power of multidisciplinary collaboration, integrating cutting-edge immunology with advanced computational biology. It not only resolves a long-standing paradox in cancer immunology but also provides a clear, actionable path for developing more effective and targeted immunotherapies for colorectal cancer, particularly the challenging MSS-MMRp subtype that affects the majority of patients.
The identification of CCR8 as a selective marker for harmful Tregs, combined with the understanding of the dual roles of IL-10-positive and IL-10-negative subtypes, marks a significant leap forward. As clinical trials testing CCR8-depleting antibodies continue to advance, the hope is that this groundbreaking research will soon translate into tangible improvements in patient outcomes, offering a new era of precision immunotherapy for a broad spectrum of cancers. The journey from fundamental discovery to clinical impact is long, but this study provides a powerful compass, guiding researchers toward a future where the immune system’s intricate mechanisms can be harnessed with unprecedented specificity to conquer cancer.
Authorship, Funding, and Disclosures
In addition to the leading authors, Dr. Alexander Rudensky, Dr. Christina Leslie, Dr. Xiao Huang, Dr. Dan Feng, and Dr. Sneha Mitra, other significant contributions to this research were made by Emma Andretta, Nima Hooshdaran, Aazam Ghelani, Eric Wang, Joe Frost, Victoria Lawless, Aparna Vancheswaran, Qingwen Jiang, Cheryl Mai, and Karuna Ganesh.
Key institutional resources at MSK played crucial roles in the execution of this complex study, including the Integrated Genomics Operation and the Single Cell Research Initiative.
Financial support for this extensive research was generously provided by the National Cancer Institute (P30 CA008748, U54 CA274492, T32 CA009512), the National Institute of Allergy and Infectious Diseases (AI034206), the Ludwig Center for Cancer Immunotherapy at MSK, the Howard Hughes Medical Institute, the Cancer Research Institute, and a Marie-Josée Kravis Fellowship in Quantitative Biology.
In the interest of transparency, Dr. Rudensky has disclosed his affiliations, which include serving on scientific advisory boards and holding equity in Sonoma Biotherapeutics, RAPT Therapeutics, Coherus Oncology, Santa Ana Bio, Odyssey Therapeutics, and Nilo Therapeutics. He is also a scientific advisory board member of Amgen, BioInvent, and Vedanta Biosciences, has consulted for AbbVie, and serves as an editor of the Journal of Experimental Medicine and an editorial advisor to Immunity. Furthermore, Dr. Rudensky and Dr. George Plitas are inventors on patents and patent applications held by MSK, specifically related to CCR8-based therapeutic depletion of tumoral Treg cells and novel antibodies targeting CCR8.
About the Author
